Edaravone Dexborneol for Treatment of Hypertensive Intracerebral Hemorrhage

Efficacy and Safety of Edaravone Dexborneol in Addition to Standard of Care in Patients With Hypertensive Intracerebral Hemorrhage: a Randomized, Double-Blind, Placebo-Controlled Trial

pending

Inclusion Criteria:

• Written informed consent from the patient or legally acceptable representative
• Males and females
• Diagnose as hypertensive intracerebral hemorrhage
• Onset of symptoms within 6~48 hours
• Position of bleeding major in basal ganglia
• The sum of scores on items 5 and 6 on the NIHSS were >= 2 at baseline and the total score (items 1-11) was >=6 and <=20
• Volume of Hematoma <= 30 ml
• Premorbid mRS score of 0 or 1

Exclusion Criteria:

• Allergy to known study drugs or excipients
• Experienced stroke in latest 3 month
• Volume of Hematoma > 5 ml in other bleeding position
• Obstructive hydrocephalus
• Any diagnosis as other than hypertensive ICH
• Unconsciousness
• Severe concurrent illness with life expectancy less than 90 days
• Pregnancy or breast-feeding